Vera Therapeutics (VERA) Projected to Post Quarterly Earnings on Wednesday

Vera Therapeutics (NASDAQ:VERA) is anticipated to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Vera Therapeutics to post earnings of ($1.34) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 12:30 PM ET.

Vera Therapeutics Stock Up 1.5%

Shares of VERA opened at $42.85 on Wednesday. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $56.05. The firm’s 50 day moving average is $47.28 and its 200-day moving average is $34.46. The stock has a market capitalization of $3.00 billion, a PE ratio of -10.74 and a beta of 1.16.

Insider Buying and Selling

In related news, Director Patrick G. Enright purchased 5,882 shares of the stock in a transaction dated Thursday, December 11th. The stock was bought at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the acquisition, the director owned 5,882 shares of the company’s stock, valued at approximately $249,985. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 16.30% of the stock is currently owned by insiders.

Institutional Trading of Vera Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock valued at $753,000 after buying an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Vera Therapeutics by 22.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after acquiring an additional 17,907 shares during the period. Jane Street Group LLC raised its stake in shares of Vera Therapeutics by 297.1% during the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after acquiring an additional 62,678 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Vera Therapeutics by 550.5% in the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after purchasing an additional 262,805 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Vera Therapeutics by 1.7% in the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after purchasing an additional 825 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

VERA has been the subject of several analyst reports. Wedbush lifted their price objective on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. The Goldman Sachs Group boosted their price target on Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Bank of America upped their price objective on shares of Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Finally, Evercore upped their price target on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.18.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.